Corneal inflammation after miniature keratoprosthesis implantation.

PURPOSE To compare corneal inflammation after syngeneic and allogeneic penetrating keratoplasty (PK) with miniature Keratoprosthesis (m-KPro) implantation in mice. METHODS BALB/C (syngeneic) or C57BL/6 (allogeneic) corneas were transplanted onto BALB/C host beds as part of PK or m-KPro implantation. Corneal inflammation was assessed by determining the frequencies of CD45(+) leukocytes, CD4(+) T cells, CD11b(+) cells, and Gr-1(+) granulocytes/monocytes by flow cytometry at 2, 4, and 8 weeks post transplantation. In addition, expression levels of the proinflammatory cytokines TNF-α and IL-1β were analyzed using real-time qPCR at 8 weeks post transplantation. RESULTS Cell frequencies in the syngeneic (syn) and allogeneic (allo) m-KPro groups were higher compared with the syngeneic and allogeneic PK groups, respectively, at all time points. However, after week 4, frequencies of all analyzed immune cells were higher in the alloPK group as compared with synKPro group. At 8 weeks, the expression of TNF-α was higher in synKPro, alloPK, and alloKPro groups compared with the naïve and synPK groups. The expression of IL-1β was significantly higher in both KPro groups as compared with PK groups. CONCLUSIONS Although the m-KPro device augments the inflammatory response in the cornea after its implantation, allogenicity (of the carrier tissue) is also a significant contributor to corneal inflammation. These data suggest that using syngeneic or decellularized corneal tissue as a Boston-KPro carrier could reduce the postoperative inflammation response.

[1]  Beatriz Munoz,et al.  Long-term outcomes of boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort. , 2014, Ophthalmology.

[2]  C. Dohlman Alkali burn to the eye: Protection using TNF-a inhibition , 2014 .

[3]  A. Shukla,et al.  UV Cross-linking of Donor Corneas Confers Resistance to Keratolysis , 2014, Cornea.

[4]  H. Lee,et al.  Intravenous Infusion of Mesenchymal Stem/Stromal Cells Decreased CCR7+ Antigen Presenting Cells in Mice with Corneal Allotransplantation , 2014, Current eye research.

[5]  Jin A. Choi,et al.  Long-term outcomes of penetrating keratoplasty in keratoconus: analysis of the factors associated with final visual acuities. , 2014, International journal of ophthalmology.

[6]  R. Dana,et al.  A novel murine model for keratoprosthesis. , 2014, Investigative ophthalmology & visual science.

[7]  Ti Wang,et al.  Photochemical activation increases the porcine corneal stiffness and resistance to collagenase digestion. , 2014, Experimental eye research.

[8]  R. Dana,et al.  Alkali Burn to the Eye: Protection Using TNF-&agr; Inhibition , 2014, Cornea.

[9]  Lucy Q. Shen,et al.  Glaucoma Progression and Role of Glaucoma Surgery in Patients With Boston Keratoprosthesis , 2014, Cornea.

[10]  A. Shukla,et al.  Wound Anatomy After Type 1 Boston KPro Using Oversized Back Plates , 2013, Cornea.

[11]  H. Lee,et al.  Analysis of macrophage phenotype in rejected corneal allografts. , 2013, Investigative ophthalmology & visual science.

[12]  M. Claesson,et al.  Clinical Outcome of Repeat Penetrating Keratoplasty , 2013, Cornea.

[13]  Michael W. Belin,et al.  Retention of the Boston keratoprosthesis type 1: multicenter study results. , 2013, Ophthalmology.

[14]  K. Lathrop,et al.  Azithromycin Treatment Increases Survival of High-Risk Corneal Allotransplants , 2013, Cornea.

[15]  S. Schwartz,et al.  POSTOPERATIVE POSTERIOR SEGMENT COMPLICATIONS IN EYES TREATED WITH THE BOSTON TYPE I KERATOPROSTHESIS , 2013, Retina.

[16]  B. Seitz,et al.  Morphological and Immunohistochemical Changes After Corneal Cross-Linking , 2013, Cornea.

[17]  K. Miyata,et al.  [Long-term outcomes of Boston keratoprosthesis]. , 2013, Nippon Ganka Gakkai zasshi.

[18]  A. Djalilian,et al.  Outcomes of Boston Keratoprosthesis Implantation for Failed Keratoplasty After Keratolimbal Allograft , 2012, Cornea.

[19]  R. Dana,et al.  Gamma-irradiation reduces the allogenicity of donor corneas. , 2012, Investigative ophthalmology & visual science.

[20]  F. Yu,et al.  International results with the Boston type I keratoprosthesis. , 2012, Ophthalmology.

[21]  J. Stein,et al.  Glaucoma Associated With Boston Type I Keratoprosthesis , 2012, Cornea.

[22]  T. Neuhann,et al.  [Results with the Boston keratoprosthesis]. , 2012, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[23]  T. Neuhann,et al.  Ergebnisse nach Boston-Keratoprothese , 2012, Der Ophthalmologe.

[24]  E. Sarchielli,et al.  Effects of riboflavin/UVA corneal cross‐linking on keratocytes and collagen fibres in human cornea , 2010, Clinical & experimental ophthalmology.

[25]  K. Tsubota,et al.  Retinal phototoxicity in a novel murine model of intraocular lens implantation , 2009, Molecular vision.

[26]  Z. Yalniz-Akkaya,et al.  Repeat Penetrating Keratoplasty: Indications and Prognosis, 1995–2005 , 2009, European journal of ophthalmology.

[27]  D. Coster,et al.  Risk Factors for Human Corneal Graft Failure Within the Australian Corneal Graft Registry , 2008, Transplantation.

[28]  R. Mohan,et al.  Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. , 2008, Experimental eye research.

[29]  J. Scott,et al.  Therapeutic keratoplasty for advanced suppurative keratitis. , 2007, American journal of ophthalmology.

[30]  R. Dana Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). , 2007, Transactions of the American Ophthalmological Society.

[31]  G. Lang [Cross linking]. , 2007, Klinische Monatsblatter fur Augenheilkunde.

[32]  James V Aquavella,et al.  Introduction to the use of the Boston keratoprosthesis , 2006 .

[33]  H. Al‐Mezaine,et al.  Repeat penetrating keratoplasty: indications, graft survival, and visual outcome , 2006, British Journal of Ophthalmology.

[34]  R. Tandon,et al.  Indications and outcome of repeat penetrating keratoplasty in India , 2005, BMC ophthalmology.

[35]  J. Naor,et al.  Outcomes of Repeat Penetrating Keratoplasty and Risk Factors for Graft Failure , 2003, Cornea.

[36]  U. Rehany,et al.  The profile of repeated corneal transplantation. , 2001, Ophthalmology.

[37]  D. Larkin,et al.  Cytokine and chemokine expression kinetics after corneal transplantation. , 2000, Transplantation.

[38]  N. P. Patel,et al.  Indications for and outcomes of repeat penetrating keratoplasty, 1989-1995. , 2000, Ophthalmology.

[39]  E. Cohen,et al.  Indications for and outcomes of repeat penetrating keratoplasty. , 1990, American journal of ophthalmology.

[40]  T. Luger,et al.  Corneal epithelial cell--derived thymocyte-activating factor (CETAF). , 1982, Investigative ophthalmology & visual science.